Abstract: Deferasirox (ICL670, marketed as Exjade) is an orally active, synthetic tridentate iron chelator originally developed and approved for the treatment of iron overload diseases such as β-thalassemia. Recently, it has garnered significant attention in the field of oncology as a potential anti-cancer therapeutic. Cancer cells exhibit altered iron metabolism, relying heavily on iron for rapid proliferation, DNA synthesis, and metastasis. By sequestering intracellular iron, Deferasirox disrupts these processes, demonstrating potent anti-proliferative and apoptotic effects across various malignancies, including leukemia, hepatoma, pancreatic, esophageal, and lung cancers. Its molecular mechanisms include the induction of cell cycle arrest, repression of the mTOR, NF-κB, and ERK signaling pathways, and the downregulation of critical cancer stem cell (CSC) markers (e.g., Nanog, SOX2, OCT3/4). Furthermore, Deferasirox exhibits synergistic effects when combined with standard chemotherapeutics, helping to overcome multi-drug resistance. While its clinical application in oncology is promising, challenges such as renal and hepatic toxicity, as well as mitochondrial disruption, necessitate further investigation to optimize its safety and efficacy in cancer therapy.
1. Introduction
Cancer cells are characterized by a marked deregulation of cellular iron metabolism. Compared to normal cells, neoplastic cells exhibit an increased demand for iron to sustain rapid proliferation, DNA synthesis (via enzymes like ribonucleotide reductase), and tumor progression [1]. This altered iron state, which often involves increased iron uptake and altered storage, presents a unique vulnerability that can be targeted therapeutically [1].
Iron chelation therapy was initially designed to prevent iron-mediated toxicity in iron overload diseases, such as β-thalassemia, where repeated blood transfusions lead to potentially fatal tissue damage [1]. While older chelators like desferrioxamine (DFO) demonstrated some anti-tumor activity, their clinical utility in oncology was severely limited by poor membrane permeability, a short plasma half-life, and the need for cumbersome subcutaneous infusions [1]. To overcome these limitations, Deferasirox (ICL670, Exjade) was developed as a lipophilic, orally active alternative [1][7]. Given that it is already clinically approved and generally well-tolerated, there is growing interest in repurposing Deferasirox as a multi-targeted anti-cancer agent capable of disrupting the complex signaling pathways that drive tumor growth and metastasis [1][2].
2. Pharmacological Activity
Deferasirox has demonstrated broad-spectrum pharmacological activity against various cancer types in both in vitro and in vivo models. It exhibits significant anti-proliferative and apoptotic effects in human hepatoma, myeloid leukemia, mantle cell lymphoma, gastric cancer, and pancreatic cancer cells in a dose-dependent manner [1][2][5]. In vivo studies have shown that Deferasirox effectively inhibits the growth of DMS-53 lung tumor xenografts and esophageal tumor xenografts (OE33, OE19, and OE21) in mice, notably without causing marked biochemical or hematological side effects [1][2]. Clinically, the administration of Deferasirox induced a remarkable complete remission in a patient suffering from chemotherapy-resistant acute monocytic leukemia [1].
Beyond its standalone efficacy, Deferasirox acts synergistically with existing anti-cancer therapies. It potentiates the effects of standard chemotherapeutic agents such as carboplatin, doxorubicin, and cisplatin, particularly in triple-negative breast cancers [2]. Furthermore, in myelodysplastic syndromes and leukemia cell lines (SKM-1, THP-1, and K-562), Deferasirox shows synergistic inhibitory effects when combined with epigenetic modifiers like decitabine and azacitidine, reducing proliferation and increasing apoptosis more effectively than either agent alone [5].
3. Molecular Mechanism of Action
The anti-tumor activity of Deferasirox is mediated through the modulation of multiple intracellular targets and signaling pathways:
Cell Cycle Arrest and Apoptosis: Deferasirox induces cell cycle arrest by modulating key regulatory proteins. In mantle cell lymphoma, it down-regulates phosphorylated retinoblastoma protein (pRb), leading to an increase in the E2F/Rb complex and subsequent G1/S phase cell cycle arrest [1]. In pancreatic cancer cells, a 10 µM dose of Deferasirox causes S phase arrest, while higher concentrations (50–100 µM) trigger apoptosis [2].
Signaling Pathway Inhibition: In acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), Deferasirox exerts its anti-leukemic activity by inhibiting extracellular signal-regulated kinase (ERK) phosphorylation and repressing the NF-κB and mammalian target of rapamycin (mTOR) signaling pathways [2]. The repression of mTOR is achieved, in part, by enhancing the expression of REDD1 [1].
Inhibition of Invasion and Metastasis: Deferasirox reduces the invasive capabilities of cancer cells. In pancreatic cancer, it inhibits invasion by reducing the activation of Cdc42 and Rac1, and its suppressive effects are associated with the downregulation of transforming growth factor-β1 (TGF-β1) [2].
Targeting Cancer Stem Cells (CSCs): A critical mechanism of Deferasirox is its ability to target CSCs, which are responsible for chemoresistance and disease recurrence. Deferasirox significantly suppresses the expression of stemness-related transcription factors, including Nanog, SOX2, OCT3/4, KLF4, and c-Myc, in a dose-dependent manner [2]. By lowering the expression of these markers, Deferasirox helps overcome resistance to conventional therapies like cisplatin [2].
Additional Mechanisms: Deferasirox upregulates the expression of the TP53 oncosuppressor gene and reduces the levels of efflux proteins such as P-glycoprotein, which are normally upregulated by iron-induced reactive oxygen species (ROS) [5]. It also influences iron storage by diverting the degradation of ferritin towards the proteasomal pathway [1].
4. Structure-Activity Relationship (SAR)
Deferasirox (4-[3, 5-bis-(hydroxyphenyl)-1, 2, 4-triazol-1-yl]-benzoic acid) is a synthetic, tridentate iron chelator [1][7]. Structurally, it requires two molecules to combine and form a stable complex with a single ferric iron atom (Fe3+), resulting in a 2:1 binding ratio [7][10]. The active molecule, ICL670, is highly lipophilic and binds firmly to plasma proteins, particularly albumin [7]. This lipophilicity is a crucial structural advantage over older hexadentate chelators like DFO, as it allows Deferasirox to easily permeate cell membranes and access intracellular iron pools [1]. Furthermore, its high and specific affinity for Fe3+, combined with a long plasma half-life (8–16 hours), provides continuous 24-hour chelating coverage, enabling a convenient once-daily oral dosing regimen [7].
5. Current Limitations
Despite its advantages, the clinical use of Deferasirox is accompanied by several limitations and safety concerns. While generally better tolerated than DFO, Deferasirox can cause extra-hematological adverse events, most notably renal impairment, hepatic impairment, gastrointestinal symptoms, and skin reactions [5]. Cases of severe toxicity have been documented, including Fanconi syndrome, bone marrow damage, and fulminant liver failure [2]. The underlying mechanism of this cellular damage is believed to involve the toxic effect of Deferasirox on mitochondria; it causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability, which disrupts cellular oxygen metabolism and ATP formation [2][3]. Consequently, its long-term effectiveness and safety profile in the context of oncology require more extensive clinical validation [1][2].
6. Future Perspectives
The future of Deferasirox in oncology lies in its potential as a synergistic agent in combination therapies. Because it effectively depletes intracellular iron and suppresses cancer stem cell markers, it can be utilized to overcome multi-drug resistance in high-grade, recurrent, and metastatic cancers [2]. Interestingly, unlike standard chemotherapeutics such as cisplatin—which can cause a compensatory release of the inflammatory cytokine IL-6 that worsens patient prognosis—Deferasirox does not induce such interleukin secretion, making it a highly strategic option for cancers like esophageal adenocarcinoma [2]. Future research and clinical trials should focus on optimizing dosing regimens to maximize anti-tumor efficacy while mitigating renal and mitochondrial toxicity. The integration of artificial intelligence and personalized medicine approaches, based on individual genetic profiles and tumor characteristics, is expected to further refine the therapeutic application of Deferasirox in cancer treatment [8].
